A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.

Trial Details

NCT ID
NCT06434597
Phase
PHASE2
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • SPH5030
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Changsha, China|28.19874,112.97087

Key Eligibility Criteria

  • Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally advanced, recurrent, metastatic and/or unresectable advanced biliary …
  • HER2 positive or HER2 gene mutation;
  • Meet the requirements of previous treatment;
  • ECOG performance status of 0 or 1；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →